<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306096</url>
  </required_header>
  <id_info>
    <org_study_id>SCANB001</org_study_id>
    <nct_id>NCT02306096</nct_id>
  </id_info>
  <brief_title>Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer</brief_title>
  <acronym>SCAN-B</acronym>
  <official_title>SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Sweden Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mrs. Berta Kamprad Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>U-CAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the genomic profiles of breast cancer in a prospective and
      population-based manner. In the first phase, breast tumors are analyzed by whole
      transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript
      isoform-level data will be analyzed in the context of patient information,
      clinicopathological variables, and outcome, with the purpose to develop new molecular
      diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses
      will be performed in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity.
      Current patient and clinicopathological evaluation is imperfect for predicting outcome, which
      results in overtreatment for many patients, and for others, leads to death from recurrent
      disease. Therefore, additional criteria are needed to better personalize care and maximize
      treatment effectiveness and survival.

      The Sweden Cancerome Analysis Network - Breast (SCAN-B) study was initiated in 2010 as a
      multicenter prospective population-based observational study with longsighted aims to analyze
      breast cancers with next-generation genomic technologies for translational research and
      integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize
      genomic data to develop and validate new clinically-actionable biomarker assays; and
      establish real-time clinical implementation of molecular diagnostic, prognostic, and
      predictive tests. In the first phase, we focus on molecular profiling by next-generation
      RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level
      data will be analyzed in the context of patient information, clinicopathological variables,
      and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer.
      Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.

      As of January 2016, over 8000 patients have enrolled in the study, representing approximately
      85% of all eligible patients within the catchment region. Tissue and blood collection is
      integrated within healthcare routines and clinical information is provided from national
      quality registries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2031</completion_date>
  <primary_completion_date type="Anticipated">August 2031</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers and clinicopathological information</measure>
    <time_frame>up to 20-years</time_frame>
    <description>Analysis of genomic data (biomarkers) and their relationship to patient and tumor clinicopathological information; assessment of analytical validity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive disease-free survival</measure>
    <time_frame>up to 20-years</time_frame>
    <description>Different biomarkers will be analysed in the context of IDFS at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-years, 5-years, 10-years, 15-years, 20-years</time_frame>
    <description>Different biomarkers will be analysed in the context of OS at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer-specific survival</measure>
    <time_frame>3-years, 5-years, 10-years, 15-years, 20-years</time_frame>
    <description>Different biomarkers will be analysed in the context of BCS at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>intraoperative</time_frame>
    <description>Different biomarkers will be analysed in the context of pathological response at time of surgery for patients receiving pre-operative therapy.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Breast Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue, whole blood, serum, plasma. Collected at diagnosis and during follow-up.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with suspected or confirmed diagnosis of primary breast cancer within
        participating hospital systems in the South Sweden Healthcare Region, Uppsala County, and
        Jönköping Country, Sweden. Additional hospital sites from within the Nordic countries are
        welcome to join.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspicion or confirmed diagnosis of primary breast cancer

          -  signed informed consent

        Exclusion Criteria:

          -  lack of signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Åke Borg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecilia Hegardt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christer Larsson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niklas Loman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Malmberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonas Manjer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Rydén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lao H Saal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Åke Borg, PhD</last_name>
    <phone>+46-46-2752552</phone>
    <email>ake.borg@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Malmberg, MD, PhD</last_name>
    <email>martin.malmberg@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallands Hospital Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>30233</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Åhlund, MD</last_name>
      <email>lars.ahlund@regionhalland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Karin Falck, MD</last_name>
      <email>anna-karin.falck@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kirurgiska kliniken</name>
      <address>
        <city>Jönköping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Asking, MD</last_name>
      <phone>+46-36-321353</phone>
      <email>bengt.asking@rjl.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blekinge County Hospital</name>
      <address>
        <city>Karlskrona</city>
        <zip>37185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Sjövall, MD</last_name>
      <email>monika.sjovall@ltblekinge.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <zip>29185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tor Svensjö, MD, PhD</last_name>
      <email>tor.svensjo@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Rydén, MD PhD</last_name>
      <phone>+46-46-176241</phone>
      <email>lisa.ryden@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Rehn, MD, PhD</last_name>
      <phone>+46-40-331892</phone>
      <email>martin.rehn@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Sjöblom, PhD</last_name>
      <phone>+46-18-4715036</phone>
      <email>tobias.sjoblom@igp.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Växjö</name>
      <address>
        <city>Växjö</city>
        <zip>35234</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Weber, MD</last_name>
      <phone>+46-470-588052</phone>
      <email>per.weber@ltkronoberg.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://scan.bmc.lu.se</url>
    <description>Sweden Cancerome Analysis Network - Breast (SCAN-B) Website (Lund University)</description>
  </link>
  <results_reference>
    <citation>Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, Brueffer C, Tang MH, Reuterswärd C, Schulz R, Karlsson A, Ehinger A, Malina J, Manjer J, Malmberg M, Larsson C, Rydén L, Loman N, Borg Å. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015 Feb 2;7(1):20. doi: 10.1186/s13073-015-0131-9. eCollection 2015.</citation>
    <PMID>25722745</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Åke Borg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prognostic and predictive biomarkers</keyword>
  <keyword>RNA-sequencing</keyword>
  <keyword>pathological complete response</keyword>
  <keyword>minimal residual disease</keyword>
  <keyword>molecular subtype</keyword>
  <keyword>gene expression profiling</keyword>
  <keyword>mutation screening</keyword>
  <keyword>BRCA</keyword>
  <keyword>translational research</keyword>
  <keyword>genomics</keyword>
  <keyword>transcriptomics</keyword>
  <keyword>proteomics</keyword>
  <keyword>metabolomics</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>circulating tumor cells</keyword>
  <keyword>circulating tumor DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon publication, the relevant anonymized individual participant data will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

